Cursos

← vista completa

Publicado el 1 de julio de 2005 | http://doi.org/10.5867/medwave.2005.06.3213

Obesidad: ¿qué hay de nuevo en tratamiento?

Obesity - what's new in treatment?

Alex Valenzuela Montero

Esta obra de Medwave está bajo una licencia Creative Commons Atribución-NoComercial 3.0 Unported. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Autores

Alex Valenzuela Montero

Presidente Sociedad Chilena de Obesidad

Figures

Article has no figures.

Foro

No hay mensajes

Historial

Citación Valenzuela Montero A. Obesity - what's new in treatment?. Medwave 2005;5(06):e3213 doi: 10.5867/medwave.2005.06.3213

Envío 01/01/1970

Aceptación 01/01/1970

Publicación 01/07/2005

Métricas

Vistas en HTML

150

Descargas en PDF

15

Total

165

% Descargas en PDF

10%

Ver detalle

Notas

Referencias

  1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999 Nov;156(11):1686-96. | PubMed
  2. Atkinson RL, Dhurandhar NV, Allison DB, Bowen RL, Israel BA, Albu JB, et al. Human adenovirus-36 is associated with increased body weight and paradoxical reduction of serum lipids. Int J Obes (Lond). 2005 Mar;29(3):281-6. | CrossRef | PubMed
  3. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004 Feb;27(2):596-601. | CrossRef | PubMed
  4. Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry. 2005 Apr;66(4):504-14. | CrossRef | PubMed
  5. Chen J. Mechanisms of action of the implantable gastric stimulator for obesity. Obes Surg. 2004 Sep;14 Suppl 1:S28-32. | CrossRef | PubMed
  6. Cruz ML, Goran MI. The metabolic syndrome in children and adolescents. Curr Diab Rep. 2004 Feb;4(1):53-62. | CrossRef | PubMed
  7. De Luca M, Segato G, Busetto L, Favretti F, Aigner F, Weiss H, et al. Progress in implantable gastric stimulation: summary of results of the European multi-center study. Obes Surg. 2004 Sep;14 Suppl 1:S33-9. | CrossRef | PubMed
  8. Dhurandhar N. Infectobesity : Obesity Infectious origin. J Nutr. 2001 Oct;131(10):2794S-2797S. | PubMed
  9. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005 Apr 16-22;365(9468):1415-28. | CrossRef | PubMed
  10. Encuesta Nacional de Salud de Chile. Ministerio de Salud de Chile, 2004.
  11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. xecutive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97. | CrossRef | PubMed
  12. Franco OH, Bonneux L, de Laet C, Peeters A, Steyerberg EW, Mackenbach JP. The Polymeal: a more natural, safer, and probably tastier strategy to reduce cardiovascular disease by more than 75%. BMJ. 2004 Dec 18;329(7480):1447-50. | CrossRef | PubMed
  13. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, American Heart Association, et al. Definition of Metabolic Syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation. 2004 Jan 27;109(3):433-8. | CrossRef | PubMed
  14. Jayaraman KS. ‘Sumo’ rats set researchers on hunt for obesity genes. Nat Med. 2005 Feb;11(2):108. | CrossRef | PubMed
  15. Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med. 2004 Jun 17;350(25):2549-57. | CrossRef | PubMed
  16. Lara-Castro C, Garvey WT. Diet, insulin resistance, and obesity: zoning in on data for Atkins dieters living in South Beach. J Clin Endocrinol Metab. 2004 Sep;89(9):4197-205. | CrossRef | PubMed
  17. Pagotto U, Pasquali R. Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet. 2005 Apr 16-22;365(9468):1363-4. | CrossRef | PubMed
  18. Valenzuela A. Obesidad. Santiago, Chile: Editorial Mediterráneo, 2002.
  19. Van Gaal L. 2-year data from the RIO-Europe Study: Metabolic effects of rimonabant in overweight/obese patients. American College of Cardiology Annual Scientific Session 2005, March 6-9, Orlando, Florida. Late Breaking Clinical Trials 2.
  20. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S; RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005 Apr 16-22;365(9468):1389-97. | CrossRef | PubMed
  21. Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: A randomized controlled trial. JAMA. 2004 Nov 10;292(18):2243-8. | CrossRef | PubMed
  22. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003 Jun 28;326(7404):1419. | CrossRef | PubMed
  23. Zemel MB, Thompson W, Milstead A, Morris K, Campbell P. Calcium and dairy acceleration of weight and fat loss during energy restriction in obese adults. Obes Res. 2004 Apr;12(4):582-90. | CrossRef | PubMed
  24. Zemmel M, et al. Calcium and dairy modulation of obesity risk. Obes Res. 2005 Jan;13(1):192-3. | CrossRef | PubMed